Is Epigral the Best Stock in Its Sector? A Look at the Numbers
- September 25, 2026
- Posted by: Kunal Singla
- Category: Market
Epigral CMP Rs 1,061 (25 Sep 2026). Market cap Rs 4,624 Cr. ROE 14.94%. P/E 17.06x versus Industry P/E 37.32x.
Quick Answer
Epigral is one of the names investors compare when screening the Chemicals sector, built on a 14.94% return on equity and a P/E of 17.06x against an Industry P/E of 37.32x. Whether Epigral is the best stock in its sector depends on whether an investor is optimising for return ratios, valuation, or both. This article breaks down the metrics, including a comparison against named Chemicals sector peers, so you can judge that for yourself.
Is Epigral the best stock in its sector? The stock trades on the NSE at Rs 1,061 as of 25 September 2026, within its 52-week range of Rs 807.00 to Rs 1,771.00. Epigral Ltd, formerly Meghmani Finechem, manufactures chloromethanes and other specialty chemicals.
Epigral sits in the Chemicals sector, and its 14.94% ROE and 17.06x P/E give a starting point for judging where it stands against comparable listed names. The rest of this article compares those numbers against verified peers and the sector’s Industry P/E benchmark.
Also read – Is Abbott India the Best Stock in Its Sector? A Look at the Numbers
Click Here – Get Free Investment Predictions
About Epigral
Epigral Ltd, formerly Meghmani Finechem, manufactures chloromethanes and other specialty chemicals. It was renamed from Meghmani Finechem, and manufactures chloromethanes and other specialty chemicals, and the stock is trading near its 52-week low. At a market capitalisation of Rs 4,624 Cr, it is tracked as part of the Chemicals sector on Univest.
Is Epigral the Best Stock in Its Sector?
Epigral makes its case as the best stock in its sector primarily on valuation relative to its Industry P/E, combining a 14.94% ROE with a 17.06x P/E against the sector’s 37.32x Industry P/E. Epigral’s 17.06x P/E is well below the 37.32x Industry P/E despite a 14.94% ROE ahead of Ellenbarrie Industrial Gases’ in this comparison, making it look inexpensive relative to its own quality, though the stock is trading near its 52-week low.
| Metric | Epigral |
|---|---|
| CMP (NSE) | Rs 1,061.40 |
| 52-Week High / Low | Rs 1,771.00 / Rs 807.00 |
| Market Cap | Rs 4,624 Cr |
| P/E (TTM) vs Industry P/E | 17.06x vs 37.32x |
| P/B | 2.08 |
| ROE | 14.94% |
| EPS (TTM) | Rs 62.82 |
| Dividend Yield | 0.47% |
| Debt to Equity | 0.26 |
Compare Epigral Against Other Chemicals Sector Stocks
How Epigral Compares Against Its Chemicals Sector Peers
The table below sets Epigral against 2 other Chemicals sector names, using the same live data source for every company. A peer average row is included for P/E, ROE and debt to equity, calculated across the 2 peer companies.
| Company | Market Cap (Rs Cr) | P/E | ROE | Debt to Equity |
|---|---|---|---|---|
| Epigral | 4,624 | 17.06 | 14.94% | 0.26 |
| Ellenbarrie Industrial Gases | 5,050 | 41.86 | 10.68% | 0.19 |
| DIC India | 609 | 21.04 | 6.51% | 0.01 |
| Peer average (2 companies) | – | 31.45 | 8.59% | 0.10 |
Against this peer set, Epigral’s 14.94% ROE is above the 8.59% peer average, and its P/E of 17.06x runs below the peer average of 31.45x. Epigral’s 17.06x P/E is well below the 37.32x Industry P/E despite a 14.94% ROE ahead of Ellenbarrie Industrial Gases’ in this comparison, making it look inexpensive relative to its own quality, though the stock is trading near its 52-week low.
What Makes Epigral Worth Watching in Chemicals
- Well below Industry P/E: A 17.06x P/E against a 37.32x Industry P/E is a significant discount for a business with a 14.94% ROE.
- Solid ROE: A 14.94% ROE is a healthy figure for a chloromethanes and specialty chemicals manufacturer.
- Chloromethanes manufacturing scale: Manufacturing chloromethanes and other specialty chemicals gives Epigral a differentiated position in the chlor-alkali value chain.
Epigral Valuation: Is It Justified?
Epigral’s 17.06x P/E is well below the 37.32x Industry P/E despite a 14.94% ROE ahead of Ellenbarrie Industrial Gases’ in this comparison, making it look inexpensive relative to its own quality, though the stock is trading near its 52-week low. As with any single stock, investors should weigh this against their own valuation discipline and risk appetite rather than the sector label alone.
Also read – Is Electronics Mart India the Best Stock in Its Sector? A Look at the Numbers
Download the Univest iOS App or Univest Android App to track Epigral and other Chemicals sector stocks.
How to Track Epigral Before You Invest
Before deciding whether Epigral deserves its label as the best stock in its sector for your own portfolio, compare it directly against Chemicals sector peers using the steps below.
- Open the Univest Screener and search for Epigral to view live price, valuation ratios, and peer comparisons within the Chemicals sector.
- Compare its P/E, P/B, and ROE against other Chemicals sector stocks before deciding if the current valuation fits your strategy.
- Set a price alert around key support and resistance zones using the Univest app so you are notified of meaningful moves.
- Open a broking account on Univest if you decide to add the stock, and size the position based on your own risk appetite and portfolio allocation.
Conclusion
Epigral earns a place in the best stock in its sector conversation on the strength of a 14.94% ROE and a P/E of 17.06x against a 37.32x Industry P/E, with named peer comparisons in this article backing up that picture. As with any individual stock decision, this analysis is educational and investors should do their own research or consult a SEBI-registered advisor before investing.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Is Epigral the best stock in its sector?
Ans. Epigral has a 14.94% ROE and trades at 17.06x P/E against a 37.32x Industry P/E, and compares above the peer average ROE of 8.59% in this article’s named comparison, so the answer depends on what an investor is prioritising.
What is the current share price of Epigral?
Ans. Epigral was trading at Rs 1,061.40 on the NSE as of 25 September 2026, within its 52-week range of Rs 807.00 to Rs 1,771.00.
What sector does Epigral belong to?
Ans. Epigral is classified under the Chemicals sector on Univest.
How does Epigral compare to its sector peers on P/E?
Ans. Epigral’s P/E of 17.06x is below the 31.45x average of the 2 named peers compared in this article.
What is Epigral’s return on equity?
Ans. Epigral reported a return on equity of 14.94%, which is above the 8.59% average of its named peers in this comparison.
Should I invest in Epigral based on its sector position?
Ans. Epigral’s sector position and metrics make it worth researching further, but any investment decision should factor in your own risk appetite, its valuation relative to peers, and independent research or advice from a SEBI-registered advisor.
